US7078383B2
(en)
*
|
1988-09-02 |
2006-07-18 |
Dyax Corp. |
ITI-D1 Kunitz domain mutants as HNE inhibitors
|
US20060134087A1
(en)
*
|
1988-09-02 |
2006-06-22 |
Dyax Corp. |
ITI-D1 Kunitz domain mutants as hNE inhibitors
|
DK0564531T3
(da)
*
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
DE69533544T2
(de)
*
|
1994-01-11 |
2006-02-23 |
Dyax Corp., Cambridge |
Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
|
US6057287A
(en)
|
1994-01-11 |
2000-05-02 |
Dyax Corp. |
Kallikrein-binding "Kunitz domain" proteins and analogues thereof
|
US20060078561A1
(en)
*
|
1994-01-31 |
2006-04-13 |
The Trustees Of Boston University |
Polyclonal antibody libraries
|
AU1736495A
(en)
|
1994-01-31 |
1995-08-15 |
Trustees Of Boston University |
Polyclonal antibody libraries
|
US6010861A
(en)
*
|
1994-08-03 |
2000-01-04 |
Dgi Biotechnologies, Llc |
Target specific screens and their use for discovering small organic molecular pharmacophores
|
US5780265A
(en)
*
|
1995-06-05 |
1998-07-14 |
Genentech, Inc. |
Kunitz type plasma kallikrein inhibitors
|
US5786328A
(en)
*
|
1995-06-05 |
1998-07-28 |
Genentech, Inc. |
Use of kunitz type plasma kallikrein inhibitors
|
US6242414B1
(en)
*
|
1995-06-07 |
2001-06-05 |
Chiron Corporation |
Regulation of cytokine synthesis and release
|
US20030199450A1
(en)
*
|
2001-04-27 |
2003-10-23 |
Chiron Corporation |
Regulation of cytokine synthesis and release
|
YU8997A
(sh)
*
|
1996-03-11 |
1999-09-27 |
Bayer Corporation |
Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
|
US5876925A
(en)
*
|
1996-10-11 |
1999-03-02 |
The Trustees Of The University Of Pennsylvania |
Magnetically activated cell sorting for production of proteins
|
US5985543A
(en)
*
|
1996-10-11 |
1999-11-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for detection of antibody binding to cells
|
US6262233B1
(en)
|
1997-01-31 |
2001-07-17 |
Human Genome Sciences, Inc. |
Tissue factor pathway inhibitor-3
|
WO1999055365A1
(en)
|
1998-04-30 |
1999-11-04 |
Cornell Research Foundation, Inc. |
Adenoviral vectors with tandem fiber proteins
|
CA2330191A1
(en)
*
|
1998-06-03 |
1999-12-09 |
Scios, Inc. |
Protease inhibitor peptides
|
CA2334170A1
(en)
|
1998-07-27 |
2000-02-10 |
Genentech, Inc. |
Improved transformation efficiency in phage display through modification of a coat protein
|
CA2342396A1
(en)
|
1998-09-11 |
2000-03-23 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
US20070140979A1
(en)
*
|
1998-12-22 |
2007-06-21 |
Bayer Aktiengesellschaft |
Method for accelerating the rate of mucociliary clearance
|
CN1229138C
(zh)
*
|
1998-12-22 |
2005-11-30 |
拜尔公开股份有限公司 |
加速粘液纤毛的清除速率的方法
|
US6294648B1
(en)
*
|
1999-07-20 |
2001-09-25 |
Bayer Corporation |
Protein having proteinase inhibitor activity
|
JP2003516755A
(ja)
*
|
1999-12-15 |
2003-05-20 |
ジェネンテック・インコーポレーテッド |
ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
|
JP2003534806A
(ja)
*
|
2000-05-31 |
2003-11-25 |
ジェンベク、インコーポレイティッド |
アデノウイルスベクターのターゲティングの方法および組成物
|
US20020150594A1
(en)
*
|
2000-06-26 |
2002-10-17 |
Maxygen, Inc. |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
EP1184393A1
(en)
*
|
2000-09-04 |
2002-03-06 |
Debiopharm S.A. |
Process for the purification of EPI-HNE proteins
|
US6989438B2
(en)
|
2000-09-04 |
2006-01-24 |
Debiopharm S.A. |
Process for the purification of EPI-HNE proteins
|
KR100826342B1
(ko)
|
2000-10-31 |
2008-05-02 |
데비오팜 에스 에이 |
Epi-hne 단백질의 현탁액, 그의 제조 방법,그로부터 유도된 건조 분말 에어로졸, 상기 현탁액 또는에어로졸을 함유하는 제약학적 조성물 및 그의 용도
|
EP1201249A1
(en)
*
|
2000-10-31 |
2002-05-02 |
Debiopharm S.A. |
Suspension of EPI-HNE-4, dry powder aerosol derived therefrom, process of preparation thereof, pharmaceutical compositions containing said suspension or aerosol, and their uses
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20040175756A1
(en)
*
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
US20060223114A1
(en)
*
|
2001-04-26 |
2006-10-05 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
US20050048512A1
(en)
*
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
AU2002256371B2
(en)
*
|
2001-04-26 |
2008-01-10 |
Amgen Mountain View Inc. |
Combinatorial libraries of monomer domains
|
US20030157561A1
(en)
*
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
US20050053973A1
(en)
*
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
KR100576674B1
(ko)
|
2001-06-20 |
2006-05-10 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
US20030148408A1
(en)
|
2001-09-18 |
2003-08-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
KR100801388B1
(ko)
|
2002-01-02 |
2008-02-05 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
WO2003062431A2
(en)
*
|
2002-01-23 |
2003-07-31 |
Debiopharm Sa |
Production of epi-hne-4 comprising reduction of improperly processed form
|
WO2003066085A1
(en)
*
|
2002-02-07 |
2003-08-14 |
Delta Biotechnology Limited |
Albumin-fused anti-angiogenesis peptides
|
US20050222023A1
(en)
*
|
2002-02-07 |
2005-10-06 |
Hans-Peter Hauser |
Albumin-fused kunitz domain peptides
|
MXPA04010092A
(es)
|
2002-04-16 |
2004-12-13 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
ATE477020T1
(de)
|
2002-06-07 |
2010-08-15 |
Dyax Corp |
Prevention und verringerung von ischemia
|
US7153829B2
(en)
|
2002-06-07 |
2006-12-26 |
Dyax Corp. |
Kallikrein-inhibitor therapies
|
CA2496925A1
(en)
*
|
2002-08-29 |
2004-03-11 |
Genentech, Inc. |
Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor
|
US6989369B2
(en)
*
|
2003-02-07 |
2006-01-24 |
Dyax Corp. |
Kunitz domain peptides
|
PL1641822T3
(pl)
|
2003-07-08 |
2013-10-31 |
Genentech Inc |
Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
|
US20050089515A1
(en)
*
|
2003-08-29 |
2005-04-28 |
Dyax Corp. |
Poly-pegylated protease inhibitors
|
CA2537113A1
(en)
*
|
2003-08-29 |
2005-03-10 |
Dyax Corp. |
Modified protease inhibitors
|
US20050164301A1
(en)
*
|
2003-10-24 |
2005-07-28 |
Avidia Research Institute |
LDL receptor class A and EGF domain monomers and multimers
|
PT2161283E
(pt)
|
2003-11-17 |
2014-08-29 |
Genentech Inc |
Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética
|
WO2005094875A1
(en)
*
|
2004-03-31 |
2005-10-13 |
Coloplast A/S |
Use of epi-hne 1-4
|
AU2005250369A1
(en)
*
|
2004-05-18 |
2005-12-15 |
Genentech, Inc. |
M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
|
EP1771212A1
(en)
*
|
2004-07-16 |
2007-04-11 |
Coloplast A/S |
A wound care device
|
US7235530B2
(en)
|
2004-09-27 |
2007-06-26 |
Dyax Corporation |
Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
|
AU2005309722B2
(en)
*
|
2004-11-22 |
2011-10-20 |
Dyax Corp. |
Plasmin-inhibitory therapies
|
WO2006091459A2
(en)
*
|
2005-02-24 |
2006-08-31 |
Joslin Diabetes Center, Inc. |
Compositions and methods for treating vascular permeability
|
MX2007010922A
(es)
|
2005-03-10 |
2007-10-12 |
Genentech Inc |
Metodos y composiciones para modular la integridad vascular.
|
JP2008541781A
(ja)
|
2005-06-06 |
2008-11-27 |
ジェネンテック・インコーポレーテッド |
異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
|
BRPI0614222A2
(pt)
*
|
2005-07-13 |
2011-03-15 |
Amgen Mountain View Inc |
proteìnas ligantes de il-6
|
WO2007021423A2
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
GB0521404D0
(en)
*
|
2005-10-20 |
2005-11-30 |
Ares Trading Sa |
Kunitz domain containing protein
|
WO2007081608A2
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
KR101453570B1
(ko)
|
2005-12-02 |
2014-10-22 |
제넨테크, 인크. |
Il-22 및 il-22r에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
|
US8993719B2
(en)
|
2005-12-29 |
2015-03-31 |
The Regents Of The University Of California |
Methods and compositions related to mutant Kunitz domain I of TFPI-2
|
HUE038243T2
(hu)
|
2005-12-29 |
2018-10-29 |
Dyax Corp |
Proteáz gátlás
|
WO2007114979A2
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
CA2649387A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
US20090142259A1
(en)
*
|
2006-05-12 |
2009-06-04 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
|
WO2008021290A2
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
ES2530438T3
(es)
|
2006-09-12 |
2015-03-02 |
Genentech Inc |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de KIT o KDR como marcador genético
|
US20100297103A1
(en)
|
2006-09-14 |
2010-11-25 |
Medical & Biological Laboratories Co., Ltd. |
Antibody having enhanced adcc activity and method for production thereof
|
WO2008091692A2
(en)
*
|
2007-01-25 |
2008-07-31 |
Joslin Diabetes Center, Inc. |
Methods of diagnosing, treating, and preventing increased vascular permeability
|
US7875431B2
(en)
|
2007-02-22 |
2011-01-25 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
EP2195010A4
(en)
*
|
2007-08-21 |
2012-03-14 |
Genzyme Corp |
TREATMENT WITH INHIBITORS OF KALLIKREINE
|
JP5566293B2
(ja)
*
|
2007-10-04 |
2014-08-06 |
バイオノミックス リミテッド |
内皮細胞マーカーおよびその使用
|
CN101186646B
(zh)
*
|
2007-10-26 |
2010-06-09 |
中国科学院昆明动物研究所 |
眼镜王蛇毒蛋白酶抑制剂及其衍生物的应用
|
JP5985150B2
(ja)
|
2007-11-07 |
2016-09-06 |
ジェネンテック, インコーポレイテッド |
微生物障害の処置のための組成物および方法
|
CA2728473A1
(en)
*
|
2008-06-20 |
2009-12-23 |
National University Corporation Okayama University |
Antibody against oxidized ldl/.beta.2gpi complex and use of the same
|
US9182406B2
(en)
*
|
2008-08-04 |
2015-11-10 |
Biodesy, Inc. |
Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
|
UA109108C2
(uk)
|
2008-12-09 |
2015-07-27 |
Дженентек, Інк. |
Антитіло до pd-l1 та його застосування для посилення функції t-клітин
|
US20110275535A1
(en)
|
2008-12-16 |
2011-11-10 |
Novartis Ag |
Yeast Display Systems
|
SI2379096T1
(sl)
|
2008-12-19 |
2020-03-31 |
Baxalta GmbH |
Zaviralci TFPI in postopki uporabe
|
EP2385843A4
(en)
*
|
2009-01-06 |
2013-02-27 |
Dyax Corp |
TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
EP3187877A1
(en)
|
2009-09-25 |
2017-07-05 |
XOMA Technology Ltd. |
Screening methods
|
WO2011050194A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
JP5856065B2
(ja)
|
2009-11-30 |
2016-02-09 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
CA3168591A1
(en)
|
2010-01-06 |
2011-07-14 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein binding proteins
|
JP5981853B2
(ja)
|
2010-02-18 |
2016-08-31 |
ジェネンテック, インコーポレイテッド |
ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
|
JP5988436B2
(ja)
|
2010-02-23 |
2016-09-07 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
WO2011115712A2
(en)
|
2010-03-19 |
2011-09-22 |
Baxter International Inc |
Tfpi inhibitors and methods of use
|
KR20130079384A
(ko)
|
2010-05-03 |
2013-07-10 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
JP2014506257A
(ja)
|
2011-01-06 |
2014-03-13 |
ダイアックス コーポレーション |
血漿カリクレイン結合タンパク質
|
CA2831136A1
(en)
|
2011-03-21 |
2012-09-27 |
Biodesy, Llc |
Classification of kinase inhibitors using nonlinear optical techniques
|
WO2012142526A1
(en)
|
2011-04-14 |
2012-10-18 |
Modiano Jaime |
Use of tumor fas expression to determine response to anti-cancer therapy
|
CA2843595C
(en)
|
2011-08-01 |
2022-10-18 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
JP2014533927A
(ja)
|
2011-09-15 |
2014-12-18 |
ジェネンテック, インコーポレイテッド |
分化を促進する方法
|
CA2850836A1
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
CN104168920A
(zh)
|
2012-01-18 |
2014-11-26 |
霍夫曼-拉罗奇有限公司 |
使用fgf19调控剂的方法
|
US20130209473A1
(en)
|
2012-02-11 |
2013-08-15 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
BR112014020173A8
(pt)
|
2012-03-16 |
2017-07-11 |
Hoffmann La Roche |
Métodos para o tratamento de um melanoma, utilizações de um inibidor, composições, conjunto, método de inibição, método de identificação, método de ajuste do tratamento e invenção
|
US9139863B2
(en)
|
2012-03-16 |
2015-09-22 |
Genentech, Inc. |
Engineered conformationally-stabilized proteins
|
WO2013137920A1
(en)
|
2012-03-16 |
2013-09-19 |
Genentech, Inc. |
Engineered conformationally-stabilized proteins
|
DK2827883T3
(da)
|
2012-03-21 |
2019-07-29 |
Baxalta GmbH |
Tfpi-inhibitorer og fremgangsmåder til anvendelse
|
EP2841951B1
(en)
|
2012-04-25 |
2019-12-11 |
Biodesy, Inc. |
Methods for detecting allosteric modulators of proteins
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
EP3556776A1
(en)
|
2012-05-31 |
2019-10-23 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists
|
EP2708235A1
(en)
*
|
2012-09-17 |
2014-03-19 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives |
Peptide antagonists of the vasopressin-2 receptor
|
WO2014128235A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
KR20150127216A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
암의 치료 및 암 약물 내성의 예방 방법
|
KR102158924B1
(ko)
|
2013-03-15 |
2020-09-22 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
JP6456356B2
(ja)
|
2013-03-15 |
2019-01-23 |
ジェネンテック, インコーポレイテッド |
IL−22ポリペプチド及びIL−22Fc融合タンパク質並びに使用方法
|
BR112015023203A8
(pt)
|
2013-03-15 |
2018-01-23 |
Constellation Pharmaceuticals Inc |
métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
|
EP3021869B1
(en)
|
2013-07-16 |
2020-07-15 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
US20150210772A1
(en)
|
2013-12-17 |
2015-07-30 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
BR112016019390B1
(pt)
*
|
2014-02-24 |
2023-11-14 |
Takeda Pharmaceutical Company Limited |
Proteínas de fusão uti, composição farmacêutica compreendendo a referida proteína, ácido nucleico, vetor de expressão, célula hospedeira recombinante e método de produção de uma proteína de fusão uti
|
KR102555955B1
(ko)
|
2014-03-27 |
2023-07-18 |
다케다 파머수티컬 컴패니 리미티드 |
당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
|
EP3636073B1
(en)
|
2014-05-05 |
2023-11-15 |
Regeneron Pharmaceuticals, Inc. |
Humanized c5 and c3 animals
|
KR20170005016A
(ko)
|
2014-05-23 |
2017-01-11 |
제넨테크, 인크. |
MiT 바이오마커 및 그의 사용 방법
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
CN114057857A
(zh)
|
2014-06-20 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
基于chagasin的支架组合物、方法和应用
|
SG11201700074YA
(en)
|
2014-07-15 |
2017-02-27 |
Genentech Inc |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
WO2016037157A2
(en)
|
2014-09-05 |
2016-03-10 |
The Johns Hopkins University |
Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
|
EP4141032B1
(en)
|
2014-11-20 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
US20160158360A1
(en)
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
EP3237906B8
(en)
|
2014-12-23 |
2020-10-28 |
Bluelight Therapeutics, Inc. |
Attachment of proteins to interfaces for use in nonlinear optical detection
|
US10376535B2
(en)
|
2015-03-26 |
2019-08-13 |
University Of Rochester |
Therapy for malignant disease
|
JP6952605B2
(ja)
|
2015-04-24 |
2021-10-20 |
ジェネンテック, インコーポレイテッド |
多特異性抗原結合タンパク質
|
EP3718569B1
(en)
|
2015-05-22 |
2023-05-03 |
Translational Drug Development, LLC |
Benzamide and active compound compositions and methods of use
|
US20180188257A1
(en)
|
2015-06-19 |
2018-07-05 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
WO2017058780A1
(en)
|
2015-09-30 |
2017-04-06 |
Merck Patent Gmbh |
Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
|
US11273151B2
(en)
|
2015-11-04 |
2022-03-15 |
Icahn School Of Medicine At Mount Sinai |
Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
|
EP3387018A1
(en)
|
2015-12-11 |
2018-10-17 |
Dyax Corp. |
Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
|
EP3405587A4
(en)
|
2015-12-23 |
2019-10-30 |
Moonshot Pharma LLC |
METHOD FOR TRIGGERING AN IMMUNE REACTION THROUGH READ THROUGH PROMOTION OF A PREVIOUS TERMINATION CODON
|
WO2017189730A1
(en)
|
2016-04-26 |
2017-11-02 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
US11292801B2
(en)
|
2016-07-05 |
2022-04-05 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
WO2018049275A1
(en)
|
2016-09-09 |
2018-03-15 |
Genentech, Inc. |
Selective peptide inhibitors of frizzled
|
CA3038331A1
(en)
|
2016-09-28 |
2018-04-05 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
IL300095A
(en)
|
2016-11-23 |
2023-03-01 |
Translational Drug Dev Llc |
Compositions of benzamide and an agonist for the cancer necrosis factor receptor superfamily and uses thereof
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
US10765762B2
(en)
|
2017-02-27 |
2020-09-08 |
Regeneron Pharmaceuticals, Inc. |
Humanized model of kidney and liver disorders
|
US20190078160A1
(en)
|
2017-04-21 |
2019-03-14 |
Genentech, Inc. |
Use of klk5 antagonists for treatment of a disease
|
US11236151B2
(en)
|
2017-04-25 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
|
US11654135B2
(en)
|
2017-06-22 |
2023-05-23 |
Moonshot Pharma Llc |
Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
|
CN111094334A
(zh)
|
2017-07-19 |
2020-05-01 |
美国卫生与公众服务部 |
用于诊断和治疗乙肝病毒感染的抗体和方法
|
WO2019126472A1
(en)
|
2017-12-22 |
2019-06-27 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
US11427932B2
(en)
*
|
2019-04-17 |
2022-08-30 |
Impossible Foods Inc. |
Materials and methods for protein production
|
WO2020227554A1
(en)
|
2019-05-09 |
2020-11-12 |
Genentech, Inc. |
Methods of making antibodies
|
JP2022534889A
(ja)
|
2019-05-24 |
2022-08-04 |
ファイザー・インコーポレイテッド |
Cdk阻害剤を使用した組合せ療法
|
CN115515616A
(zh)
|
2020-03-05 |
2022-12-23 |
代阿麦迪卡美国股份有限公司 |
乌司他丁多肽
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
CN116685325A
(zh)
|
2020-10-20 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法
|
US20220168293A1
(en)
|
2020-12-02 |
2022-06-02 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
CN112940095B
(zh)
*
|
2021-02-07 |
2022-04-15 |
西南大学 |
家蚕BmSPI51突变蛋白BmSPI51M及其制备方法和应用
|
BR112023025738A2
(pt)
|
2021-06-09 |
2024-02-27 |
Hoffmann La Roche |
Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
|
WO2023057882A1
(en)
|
2021-10-05 |
2023-04-13 |
Pfizer Inc. |
Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
|